Answers are grounded in this paper and cite their sources.
Identification of the mechanism(s) underlying the clinical response of patients with cancer treated with TA-targeted mAb is crucial to optimizing their application in the clinic and to selecting the patients most likely to benefit from their use.
No takes yet. Share an insight, caveat, or question.
Ferris et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: